scholarly article | Q13442814 |
P356 | DOI | 10.1016/S1470-2045(17)30111-0 |
P8608 | Fatcat ID | release_v66ojm2h3vf27fr3hvdfiabcai |
P698 | PubMed publication ID | 28343975 |
P50 | author | Eric Van Cutsem | Q37068027 |
Hyun Cheol Chung | Q59647646 | ||
Jaffer Ajani | Q64913003 | ||
Atsushi Ohtsu | Q115365827 | ||
P2093 | author name string | Gail D Lewis Phillips | |
Yoon-Koo Kang | |||
Betsy L Althaus | |||
Gyorgy Bodoky | |||
Hugo Castro | |||
Kohei Shitara | |||
Manish A Shah | |||
Marie-Laurence Harle-Yge | |||
Peter C Thuss-Patience | |||
Tina van der Horst | |||
Wasat Mansoor | |||
P2860 | cites work | Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial | Q27851578 |
Trastuzumab emtansine for HER2-positive advanced breast cancer | Q27851917 | ||
Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial | Q27853001 | ||
Lapatinib plus paclitaxel versus paclitaxel alone in the second-line treatment of HER2-amplified advanced gastric cancer in Asian populations: TyTAN--a randomized, phase III study | Q27853010 | ||
HER2 testing in gastric cancer: a practical approach | Q28256814 | ||
Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial | Q29620687 | ||
Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial | Q29620917 | ||
HER2 screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancer | Q30837184 | ||
Chemotherapy vs supportive care alone for relapsed gastric, gastroesophageal junction, and oesophageal adenocarcinoma: a meta-analysis of patient-level data | Q31046335 | ||
Docetaxel versus paclitaxel combined with 5-FU and leucovorin in advanced gastric cancer: combined analysis of two phase II trials | Q33576276 | ||
Trastuzumab emtansine: mechanisms of action and drug resistance | Q33759627 | ||
Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate | Q34880994 | ||
Intracellular Released Payload Influences Potency and Bystander-Killing Effects of Antibody-Drug Conjugates in Preclinical Models | Q38790625 | ||
Tumor cells chronically treated with a trastuzumab-maytansinoid antibody-drug conjugate develop varied resistance mechanisms but respond to alternate treatments | Q38913644 | ||
Trastuzumab-DM1 (T-DM1) retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancer | Q39664583 | ||
Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer--a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). | Q42608504 | ||
An adaptive seamless phase II/III design for oncology trials with subpopulation selection using correlated survival endpoints | Q44262116 | ||
Randomized, open-label, phase III study comparing irinotecan with paclitaxel in patients with advanced gastric cancer without severe peritoneal metastasis after failure of prior combination chemotherapy using fluoropyrimidine plus platinum: WJOG 400 | Q44754243 | ||
Population pharmacokinetics and exposure-response analyses of trastuzumab in patients with advanced gastric or gastroesophageal junction cancer | Q44819759 | ||
Trastuzumab-DM1 is highly effective in preclinical models of HER2-positive gastric cancer. | Q45928785 | ||
Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial | Q48117450 | ||
Salvage chemotherapy for pretreated gastric cancer: a randomized phase III trial comparing chemotherapy plus best supportive care with best supportive care alone. | Q53384216 | ||
Antibody-maytansinoid conjugates are activated in targeted cancer cells by lysosomal degradation and linker-dependent intracellular processing. | Q53599393 | ||
Level of HER2 gene amplification predicts response and overall survival in HER2-positive advanced gastric cancer treated with trastuzumab. | Q54402875 | ||
A Phase II trial of vinorelbine in patients with advanced gastroesophageal adenocarcinoma | Q79733212 | ||
P433 | issue | 5 | |
P921 | main subject | adenocarcinoma | Q356033 |
trastuzumab | Q412616 | ||
P304 | page(s) | 640-653 | |
P577 | publication date | 2017-03-23 | |
P1433 | published in | Lancet Oncology Commission | Q13747613 |
P1476 | title | Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 study | |
P478 | volume | 18 |
Search more.